论文部分内容阅读
目的:研究凋亡调控基因livin和caspase-3在婴幼儿血管瘤组织中的表达及与细胞凋亡的关系,探讨其变化对血管瘤病程演化的影响。方法:采用免疫组织化学SABC法检测血管瘤组织标本中livin和caspase-3的表达,同时采用末端转移酶介导的原位缺口末端标记染色(TUNEL)技术检测血管瘤细胞的凋亡情况。应用SPSS17.O软件包对结果进行统计学分析。结果:Caspase-3阳性表达率在增殖期和消退期血管瘤分别为42.31%和81.82%,2组之间差异显著(P<0.01);Caspase-3在血管畸形和正常皮肤组织不表达或低表达。Livin阳性表达率在增殖期和消退期血管瘤分别为88.46%和31.82%,2组之间差异显著(P<0.01);Livin在血管畸形和正常皮肤组织不表达或低表达。Livin与caspase-3的表达呈负相关(r=-0.539,P<0.01)。血管瘤消退期细胞凋亡显著高于增殖期,在血管瘤内皮细胞中,Livin与凋亡呈负相关(r=-0.640,P=0.004),而caspase-3与凋亡呈正相关(r=0.471,P=0.042)。结论:Livin和caspase-3与血管瘤的发生、发展密切相关。
Objective: To investigate the expression of apoptosis-controlling genes livin and caspase-3 in infantile hemangiomas and their relationship with apoptosis, and to explore the effect of these changes on the course of hemangiomas. Methods: The expressions of livin and caspase-3 in hemangiomas were detected by immunohistochemical SABC method. Apoptosis of hemangiomas was detected by telomerase-mediated terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL). SPSS17.O software package for statistical analysis of the results. Results: The positive rates of Caspase-3 in proliferative and remission hemangiomas were 42.31% and 81.82%, respectively. There was significant difference between the two groups (P <0.01). Caspase-3 expression in vascular malformations and normal skin tissues was not significantly lower expression. The positive expression rate of Livin was 88.46% and 31.82% respectively in proliferative phase and regression group, with significant difference between the two groups (P <0.01). The expression of Livin in vascular malformations and normal skin tissues was either underexpressed or down-regulated. Livin and caspase-3 expression was negatively correlated (r = -0.539, P <0.01). There was a negative correlation between Livin and apoptosis in hemangioma endothelial cells (r = -0.640, P = 0.004), but caspase-3 was positively correlated with apoptosis (r = 0.471, P = 0.042). Conclusion: Livin and caspase-3 are closely related to the occurrence and development of hemangiomas.